RecruitingPhase 3NCT06605118

Azithromycin Prophylaxis for PRElabor CEsarean DElivery Trial

Azithromycin Prophylaxis for Prelabor Cesarean Delivery Trial


Sponsor

The George Washington University Biostatistics Center

Enrollment

8,000 participants

Start Date

Nov 6, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

This is a phase-III multi-center double-blind randomized controlled trial of 8,000 individuals undergoing a scheduled or prelabor cesarean delivery who are randomized to either adjunctive azithromycin prophylaxis or to placebo. Both groups also will receive standard of care preoperative antibiotics (excluding azithromycin). The primary endpoint is a maternal infection composite defined as any one of the following up to 6 weeks postpartum: endometritis, wound infection, abscess, septic thrombosis, sepsis, pneumonia, pyelonephritis and breast infection.


Eligibility

Sex: FEMALE

Inclusion Criteria3

  • ≥ 23 weeks' gestation (ACOG dating criteria)
  • Scheduled or prelabor cesarean delivery
  • Singleton or twin gestation

Exclusion Criteria12

  • Allergy or contraindication to azithromycin or macrolide antibiotics, including those with a history of cholestatic jaundice/hepatic dysfunction associated with prior use of azithromycin
  • Chorioamnionitis
  • Bacterial infection (e.g., pyelonephritis) requiring ongoing antibiotic treatment after delivery
  • Premature rupture of membranes (PROM) or labor (i.e., contractions with ongoing cervical change)
  • Fetal demise or known major congenital anomaly
  • Azithromycin treatment within 7 days
  • Planned use of antimicrobial prophylaxis after delivery for any reason
  • Known structural heart disease or active cardiomyopathy (current ejection fraction\<40%)
  • Known arrhythmia with QT prolongation or taking scheduled medications known to prolong the QT interval such that it would preclude the use of azithromycin
  • Refusal or unable to obtain consent (e.g., language barrier)
  • Participating in another intervention study that influences the primary outcome in this study
  • Participation in this trial in a previous pregnancy. Patients who were screened in a previous pregnancy, but not randomized, do not have to be excluded.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGAzithromycin Injection

500mg azithromycin in 250 mL of normal saline

DRUGPlacebo

250 mL of normal saline

DRUGStandard of Care Preoperative antibiotics

standard of care preoperative antibiotics (excluding azithromycin) prior to incision


Locations(14)

University of Alabama - Birmingham

Birmingham, Alabama, United States

Regents of the University of California San Francisco

San Francisco, California, United States

Northwestern University

Chicago, Illinois, United States

Columbia University

New York, New York, United States

University of North Carolina - Chapel Hill

Chapel Hill, North Carolina, United States

Duke University

Durham, North Carolina, United States

Case Western Reserve University

Cleveland, Ohio, United States

Ohio State University

Columbus, Ohio, United States

Hospital of the University of Pennsylvania

Philadelphia, Pennsylvania, United States

Magee Women's Hospital

Pittsburgh, Pennsylvania, United States

Brown Univeristy

Providence, Rhode Island, United States

Baylor College of Medicine

Houston, Texas, United States

University of Texas - Houston

Houston, Texas, United States

University of Utah

Salt Lake City, Utah, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06605118


Related Trials